The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications
Postmarketing Studies and Clinical Trials — Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act
Reports on the Status of Postmarketing Study Commitments — Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997
Draft Guidance: Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines
Regulations and Policies and Procedures for Postmarketing Surveillance Programs
Postmarketing Surveillance Programs
Postmarketing Surveillance and Epidemiology: Human Drugs
Postmarketing Drug Safety Evaluations
Adverse Event Reporting System (AERS)
Development and Use of RiskMinimization Action Plans
Establishing Pregnancy Exposure Registries
Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment
Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims
Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report
Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products
Computerized Systems Used in Clinical Investigations
Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using
Electronic Healthcare Data Sets
Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS
Assessments, and Proposed REMS Modifications
Medication Guides--Distribution Requirements and Inclusion of Medication Guides in Risk
Evaluation and Mitigation Strategies
Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act
Pharmacovigilance Planning